Not FDA-approved · the FDA's words and sellers' current prices

Can you still get compounded tirzepatide and semaglutide?

Last updated

Prices checked through Nov 17, 2026 · FDA page read Nov 4, 2026

Yes, as of November 2026: 451 US sellers publish a current price for compounded tirzepatide and 462 for compounded semaglutide, read on their own pages. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, which ended the exemption that let pharmacies make copies in bulk, and it has sent warning letters to compounders since. Compounding is now generally limited to patient-specific prescriptions, and compounded drugs are not FDA-approved. FDA on the shortages (fda.gov) (FDA: policies for compounders as the GLP-1 supply stabilizes) FDA on compounded GLP-1s (fda.gov) (FDA: concerns with unapproved GLP-1 drugs used for weight loss)

Lowest prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

By medicine: Is compounded tirzepatide legal? · Is compounded semaglutide legal?

Today

Who still sells it, and from what price

  • Compounded tirzepatide

    451 US sellers publish a current price, lowest ≈ $128 per 30 days at Potere Health MD where the supply is stated.

    FDA says the shortage was resolved in December 2024 (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize). As of May 31, 2026 it had received more than 730 adverse event reports (fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss).

    FDA-approved tirzepatide starts at $320 per 30 days.

    Every compounded tirzepatide price, lowest first

  • Compounded semaglutide

    462 US sellers publish a current price, lowest ≈ $55 per 30 days at Aspire Health where the supply is stated.

    FDA says the shortage was resolved in February 2025 (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize). As of May 31, 2026 it had received 990 adverse event reports (fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss).

    FDA-approved semaglutide starts at $149 per 30 days.

    Every compounded semaglutide price, lowest first

The FDA's words

What the FDA has said since the shortages ended

  • Its statement to compounders, Apr 1, 2026 FDA (fda.gov) (FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize)

    “The drug product is compounded for an individual patient based on receipt of a prescription.”

    “The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product.”

    “This is unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.”

    The FDA says “it does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.”

    “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

  • “Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy.” FDA (fda.gov) (FDA: concerns with unapproved GLP-1 drugs used for weight loss)
  • “Specifically, your firm compounded products including TIRZEPATIDE/NIACINAMIDE (4 ML)(17/2 MG/ML), SEMAGLUTIDE/CYANOCOBALAMIN (1 ML)(5/0.5 MG/ML), and TIRZEPATIDE/NIACINAMIDE (2.5 ML)(8/2 MG/ML), which appear to be essentially copies of FDA-approved semaglutide and tirzepatide products.” and “The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual.” From its letter of Sep 18, 2026 to Empower Pharmacy. FDA letter (fda.gov) (FDA warning letter to Empower Pharmacy)
  • “During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA.” From its letter of Apr 7, 2026 to ProRx LLC. FDA letter (fda.gov) (FDA warning letter to ProRx)
  • “During the inspection, the investigators noted serious deficiencies in your practices for producing drug products, which put patients at risk.” From its letter of Jan 16, 2026 to Boothwyn Pharmacy, LLC. FDA letter (fda.gov) (FDA warning letter to Boothwyn Pharmacy)

Every FDA warning letter naming a GLP-1 · which pharmacy each seller names · what each seller adds

Read on their own pages

Hims, Hers and Ro

Ro does: its own page (ro.co/lp/weight-loss/compounded-semaglutide, read Nov 14, 2026) prices compounded semaglutide at $399/mo, and it is not offered in Alabama, Alaska, Arkansas, California, Hawaii, Louisiana, Mississippi, Virginia, and the District of Columbia. The weight-loss pages of Hims and Hers, read Nov 15, 2026, do not use the word compounded and name FDA-approved brands. Hims & Hers' own announcement of Mar 9, 2026 says: "For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary." Ask them what is on offer now, since a page can change. The sellers that publish a compounded price are listed on the price pages here. Their weight-loss pages: Hims (hims.com) (Hims weight-loss page) (read Nov 15, 2026), Hers (forhers.com) (Hers weight-loss page) (read Nov 15, 2026), Ro (ro.co) (Ro weight-loss page) (read Nov 6, 2026).

Questions

Common questions

Can you still get compounded tirzepatide?

451 US sellers publish a current price for it, from ≈ $128 per 30 days at Potere Health MD where the supply is stated. The FDA declared the tirzepatide shortage resolved in December 2024. A prescriber and a pharmacy decide whether a given prescription fits the limits on compounding. FDA: policies for compounders as the GLP-1 supply stabilizes

Can you still get compounded semaglutide?

462 US sellers publish a current price for it, from ≈ $55 per 30 days at Aspire Health where the supply is stated. The FDA declared the semaglutide shortage resolved in February 2025. A prescriber and a pharmacy decide whether a given prescription fits the limits on compounding. FDA: policies for compounders as the GLP-1 supply stabilizes

Is compounded tirzepatide legal?

The FDA declared the shortage resolved in December 2024, which ended the exemption that let pharmacies make copies of the approved drug in bulk. In its statement of April 1, 2026, the conditions include: "The drug product is compounded for an individual patient based on receipt of a prescription", and "The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product." It also says: "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list." Whether one prescription fits those limits is for the prescriber and the pharmacy to decide. FDA: policies for compounders as the GLP-1 supply stabilizes

Is compounded semaglutide being discontinued?

No date has been set that we have read. 462 US sellers still publish a price today, and the FDA has been writing to compounders since the shortage ended. A seller can stop at any time, so check its page before you rely on a supply.

Did the FDA ban compounded semaglutide and tirzepatide?

No ban has been issued. The shortages ended, and with them the exemption for making copies in bulk. FDA's statement of April 1, 2026 sets the conditions for a pharmacy compounding them, including "The drug product is compounded for an individual patient based on receipt of a prescription" and "The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product." The FDA has sent warning letters to pharmacies, and in its letter of Sep 18, 2026 to Empower Pharmacy it wrote: "The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual." FDA's statement of April 1, 2026

What happened in the compounded tirzepatide lawsuit?

The compounders lost their appeals. In Outsourcing Facilities Association v. FDA (No. 25-10600), the US Court of Appeals for the Fifth Circuit reviewed FDA's decision on Mounjaro and Zepbound and, in its opinion filed Aug 27, 2026, wrote: "The FDA removed these tirzepatide-injection products from its drug shortage list in October 2024 ... The district court concluded that the FDA did not violate the APA in either respect. We affirm." In the semaglutide case decided the same day (No. 25-10758, Ozempic and Wegovy), it wrote: "Any error by the FDA in not proceeding through the APA’s notice and comment procedures was harmless, and the FDA’s ultimate action was not arbitrary or capricious." The court marked both opinions: "This opinion is not designated for publication. See 5th Cir. R. 47.5." (ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf and ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf, read Nov 15, 2026.) A pharmacy filling one patient's prescription still works under the conditions in FDA's statement of April 1, 2026, quoted above, and 451 US sellers publish a current compounded tirzepatide price. The Fifth Circuit's opinion of Aug 27, 2026

Will compounded tirzepatide and semaglutide be banned?

No ban has been announced that we have read. What is pending is narrower. In the Federal Register of May 1, 2026, FDA published "FDA's proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List", the list of ingredients that outsourcing facilities registered under section 503B may compound from. Comments closed Jul 30, 2026, under the extension FDA published in the Federal Register of Jun 26, 2026, and we found no final notice when we last read the Federal Register (Nov 6, 2026). A pharmacy filling one patient's prescription works under the conditions in FDA's statement of April 1, 2026, quoted above. A seller can stop at any time, so check its page before you rely on a supply. The Federal Register notice of May 1, 2026

Does Hims & Hers sell compounded tirzepatide?

No. Eli Lilly's announcement with Hims & Hers of Nov 6, 2026 says: "Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future." Under that agreement Hims & Hers sells Lilly's FDA-approved Zepbound and Foundayo at Lilly's own self-pay prices: "Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound." Hims' own page states its membership as a separate monthly charge; both, each with the day it was read, are on the Hims & Hers seller page here. Lilly's announcement of Nov 6, 2026

Is compounded tirzepatide with B12 still allowed?

Some sellers list it. The FDA's statement of April 1, 2026 says: "FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug product" when the route is the same and the strengths are within 10%. In its letter of Sep 18, 2026 to Empower Pharmacy, it wrote: "Specifically, your firm compounded products including TIRZEPATIDE/NIACINAMIDE (4 ML)(17/2 MG/ML), SEMAGLUTIDE/CYANOCOBALAMIN (1 ML)(5/0.5 MG/ML), and TIRZEPATIDE/NIACINAMIDE (2.5 ML)(8/2 MG/ML), which appear to be essentially copies of FDA-approved semaglutide and tirzepatide products." Which sellers state an additive is on the additives page.

Can you still get compounded semaglutide from Hims, Hers or Ro?

Ro does: its own page (ro.co/lp/weight-loss/compounded-semaglutide, read Nov 14, 2026) prices compounded semaglutide at $399/mo, and it is not offered in Alabama, Alaska, Arkansas, California, Hawaii, Louisiana, Mississippi, Virginia, and the District of Columbia. The weight-loss pages of Hims and Hers, read Nov 15, 2026, do not use the word compounded and name FDA-approved brands. Hims & Hers' own announcement of Mar 9, 2026 says: "For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary." Ask them what is on offer now, since a page can change. The sellers that publish a compounded price are listed on the price pages here. Hims & Hers' announcement of Mar 9, 2026

How much does the FDA-approved version cost instead?

FDA-approved tirzepatide starts at $320 per 30 days and FDA-approved semaglutide at $149 per 30 days at the starting dose, without insurance, from the makers' own programs and other sellers listed here.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.